Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC468714284;14285;14286 chr2:178739174;178739173;178739172chr2:179603901;179603900;179603899
N2AB437013333;13334;13335 chr2:178739174;178739173;178739172chr2:179603901;179603900;179603899
N2ANoneNone chr2:Nonechr2:None
N2B432413195;13196;13197 chr2:178739174;178739173;178739172chr2:179603901;179603900;179603899
Novex-1444913570;13571;13572 chr2:178739174;178739173;178739172chr2:179603901;179603900;179603899
Novex-2451613771;13772;13773 chr2:178739174;178739173;178739172chr2:179603901;179603900;179603899
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: A
  • RefSeq wild type transcript codon: GCA
  • RefSeq wild type template codon: CGT
  • Domain: Ig-29
  • Domain position: 82
  • Structural Position: 168
  • Q(SASA): 0.3462
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
A/P rs1291988238 None 0.055 N 0.467 0.075 None gnomAD-3.1.2 6.57E-06 None None None None N None 2.41E-05 0 0 0 0 None 0 0 0 0 0
A/T None None None N 0.155 0.11 None gnomAD-4.0.0 1.88892E-06 None None None None N None 0 0 None 0 0 None 2.01743E-05 0 0 0 0
A/V None None 0.001 N 0.209 0.067 None gnomAD-4.0.0 7.33699E-07 None None None None N None 0 0 None 0 0 None 0 0 9.3863E-07 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
A/C 0.4015 ambiguous 0.4048 ambiguous -0.713 Destabilizing 0.356 N 0.459 neutral None None None None N
A/D 0.245 likely_benign 0.2858 benign -0.793 Destabilizing 0.016 N 0.445 neutral None None None None N
A/E 0.156 likely_benign 0.1859 benign -0.923 Destabilizing None N 0.263 neutral N 0.434227662 None None N
A/F 0.2601 likely_benign 0.2926 benign -1.0 Destabilizing 0.214 N 0.582 neutral None None None None N
A/G 0.1496 likely_benign 0.1581 benign -0.645 Destabilizing 0.012 N 0.349 neutral N 0.51116012 None None N
A/H 0.3577 ambiguous 0.388 ambiguous -0.765 Destabilizing 0.356 N 0.509 neutral None None None None N
A/I 0.198 likely_benign 0.2138 benign -0.391 Destabilizing 0.038 N 0.461 neutral None None None None N
A/K 0.2225 likely_benign 0.2477 benign -0.929 Destabilizing None N 0.271 neutral None None None None N
A/L 0.1555 likely_benign 0.1823 benign -0.391 Destabilizing 0.006 N 0.385 neutral None None None None N
A/M 0.1747 likely_benign 0.1961 benign -0.329 Destabilizing 0.007 N 0.335 neutral None None None None N
A/N 0.2026 likely_benign 0.2277 benign -0.517 Destabilizing 0.038 N 0.492 neutral None None None None N
A/P 0.5628 ambiguous 0.6665 pathogenic -0.398 Destabilizing 0.055 N 0.467 neutral N 0.511977946 None None N
A/Q 0.2176 likely_benign 0.245 benign -0.797 Destabilizing 0.003 N 0.333 neutral None None None None N
A/R 0.1877 likely_benign 0.2149 benign -0.444 Destabilizing 0.038 N 0.483 neutral None None None None N
A/S 0.0818 likely_benign 0.0839 benign -0.73 Destabilizing None N 0.185 neutral N 0.344466617 None None N
A/T 0.0706 likely_benign 0.0718 benign -0.781 Destabilizing None N 0.155 neutral N 0.381920567 None None N
A/V 0.1164 likely_benign 0.1225 benign -0.398 Destabilizing 0.001 N 0.209 neutral N 0.477773784 None None N
A/W 0.6301 likely_pathogenic 0.6679 pathogenic -1.194 Destabilizing 0.864 D 0.531 neutral None None None None N
A/Y 0.3577 ambiguous 0.3789 ambiguous -0.84 Destabilizing 0.356 N 0.575 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.